Your browser is no longer supported. Please, upgrade your browser.
Settings
CORV Correvio Pharma Corp. daily Stock Chart
CORV [NASD]
Correvio Pharma Corp.
Index- P/E- EPS (ttm)-0.47 Insider Own0.80% Shs Outstand39.45M Perf Week-4.59%
Market Cap106.52M Forward P/E- EPS next Y-0.35 Insider Trans- Shs Float38.04M Perf Month-21.05%
Income-16.60M PEG- EPS next Q-0.20 Inst Own76.60% Short Float3.67% Perf Quarter-5.92%
Sales28.70M P/S3.71 EPS this Y29.50% Inst Trans-0.19% Short Ratio7.78 Perf Half Y-24.37%
Book/sh0.19 P/B14.21 EPS next Y50.00% ROA-26.80% Target Price7.80 Perf Year13.92%
Cash/sh0.40 P/C6.83 EPS next 5Y28.00% ROE-162.10% 52W Range1.99 - 5.24 Perf YTD8.43%
Dividend- P/FCF- EPS past 5Y-26.80% ROI-16.30% 52W High-48.47% Beta0.67
Dividend %- Quick Ratio2.80 Sales past 5Y44.80% Gross Margin71.10% 52W Low35.68% ATR0.23
Employees173 Current Ratio3.20 Sales Q/Q27.10% Oper. Margin-27.60% RSI (14)34.89 Volatility8.26% 7.63%
OptionableYes Debt/Eq6.01 EPS Q/Q-727.90% Profit Margin-57.80% Rel Volume0.28 Prev Close2.79
ShortableYes LT Debt/Eq6.01 EarningsMar 13 BMO Payout- Avg Volume179.27K Price2.70
Recom1.60 SMA20-9.98% SMA50-18.99% SMA200-25.38% Volume50,074 Change-3.23%
Dec-04-18Initiated B. Riley FBR Buy $7
Oct-12-18Upgrade Mackie Research Hold → Buy
Apr-09-19 09:45AM  Cannabis Industry Consuming Energy at An Alarming Rate: Investing in Solutions ACCESSWIRE
Apr-03-19 09:29AM  Correvio Announces Zevtera® Abstracts at ECCMID 2019 CNW Group
09:28AM  Correvio Announces Xydalba (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019 PR Newswire
09:28AM  Correvio Announces Xydalba (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019 CNW Group
Apr-02-19 08:00AM  Correvio to present at the H.C. Wainwright Global Life Sciences Conference CNW Group
Mar-20-19 08:00AM  Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting PR Newswire -5.39%
Mar-14-19 07:00AM  Correvio Announces at the Market Offering PR Newswire
Mar-13-19 07:00AM  Correvio Reports Fourth Quarter and Full Year 2018 Financial Results CNW Group -7.14%
Mar-11-19 08:00AM  Correvio Announces Amendment To Term Loan With CRG-Managed Funds CNW Group +5.79%
Mar-07-19 08:00AM  Correvio to Present at Upcoming Investor Conferences PR Newswire +5.68%
08:00AM  Correvio to Present at Upcoming Investor Conferences CNW Group
Mar-06-19 08:00AM  Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019 PR Newswire
08:00AM  Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019 CNW Group
Feb-21-19 08:00AM  Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire
Feb-07-19 08:00AM  Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress CNW Group +19.35%
Jan-17-19 08:00AM  Correvio Provides Update On At The Market Offering PR Newswire +25.88%
Jan-02-19 08:00AM  Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes CNW Group
Nov-26-18 10:00AM  CORV: Topline Growth Accelerating Zacks Small Cap Research
Nov-20-18 07:00AM  Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference CNW Group
Nov-06-18 04:00PM  Correvio Reports Third Quarter 2018 Financial Results CNW Group
Oct-31-18 10:00AM  CORV: Brinavess Continues to Hit Milestones Zacks Small Cap Research -6.11%
Oct-30-18 07:00AM  Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018 CNW Group
Oct-29-18 07:00AM  Correvio Announces Brinavess Eligibility for Patent Extension PR Newswire
07:00AM  Correvio Announces Brinavess Eligibility for Patent Extension CNW Group
Oct-23-18 07:00AM  Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019 PR Newswire +25.96%
Oct-01-18 09:15AM  CORV: Brinavess Continues to Lead Zacks Small Cap Research -5.47%
Sep-20-18 04:01PM  Correvio to Participate In Upcoming Investor Conferences PR Newswire
Sep-05-18 07:00AM  Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study PR Newswire +13.77%
Sep-04-18 07:00AM  Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics CNW Group
Aug-31-18 02:44PM  Penny Stocks to Watch for September 2018 Investopedia
Aug-28-18 07:00AM  Correvio to Participate in Upcoming Investor Conferences CNW Group
Aug-16-18 07:00AM  Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients PR Newswire +11.40%
Aug-14-18 04:00PM  Correvio Reports Second Quarter 2018 Financial Results PR Newswire
04:00PM  Correvio Reports Second Quarter 2018 Financial Results CNW Group
02:30PM  Cardiome Pharma Corp. to Host Earnings Call ACCESSWIRE
07:00AM  Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China PR Newswire
Aug-07-18 08:00AM  Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018 CNW Group
Aug-01-18 08:00AM  Correvio to present at the Canaccord Genuity 38th Annual Growth Conference CNW Group
Jul-10-18 08:49AM  Correvio Announces At The Market Offering CNW Group
Jun-29-18 09:00AM  Penny Stocks to Buy Using Technical Analysis Investopedia
Jun-14-18 04:13PM  What You Must Know About Correvio Pharma Corps (TSE:CORV) Financial Strength Simply Wall St.
Jun-12-18 08:10AM  Todays Research Reports on Stocks to Watch: CRISPR Therapeutics and Cardiome Pharma ACCESSWIRE +16.33%
Jun-11-18 08:00AM  Correvio Provides U.S. Regulatory Update for BRINAVESS PR Newswire +44.23%
Jun-06-18 08:00AM  Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS CNW Group
May-31-18 05:46PM  Where Correvio Pharma Corps (TSE:CORV) Earnings Growth Stands Against Its Industry Simply Wall St.
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. Its portfolio of marketed brands also comprise Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome; and Esmocard and Esmocard Lyo (esmolol hydrochloride), a short-acting betablocker used to control rapid heart rate in various cardiovascular indications. The company's product candidates that are in development include Trevyent, a drug device combination that is designed to deliver treprostinil for pulmonary arterial hypertension. Correvio Pharma Corp. is headquartered in Vancouver, Canada.